

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *			2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
Kirson Eilon D.			NovoCure Ltd [NVCR]			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> X Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Science Officer		
(Last) (First) (Middle)			3. Date of Earliest Transaction (MM/DD/YYYY)					
C/O NOVOCURE INC., VALLEY STREAM PARKWAY, SUITE 300			1/16/2019					
(Street)			4. If Amendment, Date Original Filed (MM/DD/YYYY)			6. Individual or Joint/Group Filing (Check Applicable Line)		
MALVERN, PA 19355						<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
(City) (State) (Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares	1/16/2019		M		100000 (1)	A	\$14.37	209063	D	
Ordinary Shares	1/16/2019		S		100000	D	\$45.11 (2)	109063	D	
Ordinary Shares	1/17/2019		M		68813 (1)	A	\$14.37	177876	D	
Ordinary Shares	1/17/2019		S		68813	D	\$45.25 (3)	109063	D	

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Options to Buy Ordinary Shares	\$14.37	1/16/2019		M		100000		(4)	2/23/2025	Ordinary Shares	100000	\$0.00	135335	D	
Options to Buy Ordinary Shares	\$14.37	1/17/2019		M		68813		(4)	2/23/2025	Ordinary Shares	68813	\$0.00	66522	D	

Explanation of Responses:

- Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson.
- On January 16, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 100,000 shares in multiple trades at prices ranging from \$45.00 to \$45.36. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- On January 17, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 68,813 shares in multiple trades at prices ranging from \$45.00 to \$45.66. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- Fully vested and currently exercisable as of the date hereof.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Kirson Eilon D. C/O NOVOCURE INC., VALLEY STREAM PARKWAY, SUITE 300 MALVERN, PA 19355			Chief Science Officer	

